Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Aobaixin
- ·The full record, as it builds
Funding rounds
No funding rounds for Aobaixin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aobaixin
Developer of nucleic acid drug intended for targeted cancer therapy and molecular delivery. The company offers multi-phosphatase catalytic systems and specialized delivery technologies for small nucleic acid drugs, supporting multiple R&D pipelines including anti-KRAS siRNA therapies for pancreatic cancer, enabling pharmaceutical and biotech markets to advance precision medicine, improve intracellular delivery efficiency, and accelerate clinical translation of gene-targeted treatments.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Website
- allbiosyn.com/
- Ownership
- Privately Held (backing)
Aobaixin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aobaixin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aobaixin in its N-PORT filings yet. We sweep new filings monthly.